Article

The Silver Lining in BET Protein Targeting for Advanced Prostate Cancer Pharmacotherapy: Recent Updates

2024-08-26

Abstract excerpt

Despite advances made over the years in the pharmacotherapy of prostate cancer, progression to the advanced phenotypes which ultimately account for the high rate of mortality in patients continue to pose a significant challenge to clinical management and outcomes. Recent integrative strategies geared towards the identification of beneficial molecules have identified the role of epigenetics and in turn BET proteins...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9f2a853a-d36c-5583-af41-38e534e5debb
DOI: 10.22541/au.172471558.80712518/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The Silver Lining in BET Protein Targeting for Advanced Prostate Cancer Pharmacotherapy: Recent UpdatesDOI 10.22541/au.172471558.80712518/v1Read

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsSemantic proximity Read

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancerSemantic proximity Read

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerSemantic proximity Read

BET bromodomain inhibitors—A novel epigenetic approach in castration-resistant prostate cancerSemantic proximity Read

Small-Molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic PotentialSemantic proximity Read

Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of ProteinsSemantic proximity Read

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read

Precision Targeting of BET Proteins - Navigating Disease Pathways, Inhibitor Insights, and Shaping Therapeutic Frontiers: A Comprehensive ReviewSemantic proximity Read

Targeting BET Bromodomains in CancerSemantic proximity Read

HF-125, a first-in-class computer-modeled novel inhibitor of Tribbles 2, for therapy of enzalutamide resistant, neuroendocrine prostate cancerSemantic proximity Read

Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate CancerSemantic proximity Read

Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidenceSemantic proximity Read